A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma

Salima Ismail, Malek Meskawi, Jens Hansen, Marco Bianchi, Zhe Tian, Mathieu Latour, Markus Graefen, Francesco Montorsi, Quoc Dien Trinh, Paul Perrotte, Pierre I. Karakiewicz, Maxine Sun

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies.

Original languageEnglish
Pages (from-to)49-57
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume90
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Therapeutics
Disease-Free Survival
Clear-cell metastatic renal cell carcinoma
temsirolimus
Guidelines
sunitinib
Erlotinib Hydrochloride
sorafenib

Keywords

  • Chromophobe
  • Metastatic
  • Non-clear cell
  • Papillary
  • Renal cell carcinoma
  • Sorafenib
  • Sunitinib
  • Systemic therapy
  • Targeted therapy
  • Temsirolimus

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma. / Ismail, Salima; Meskawi, Malek; Hansen, Jens; Bianchi, Marco; Tian, Zhe; Latour, Mathieu; Graefen, Markus; Montorsi, Francesco; Trinh, Quoc Dien; Perrotte, Paul; Karakiewicz, Pierre I.; Sun, Maxine.

In: Critical Reviews in Oncology/Hematology, Vol. 90, No. 1, 2014, p. 49-57.

Research output: Contribution to journalArticle

Ismail, S, Meskawi, M, Hansen, J, Bianchi, M, Tian, Z, Latour, M, Graefen, M, Montorsi, F, Trinh, QD, Perrotte, P, Karakiewicz, PI & Sun, M 2014, 'A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma', Critical Reviews in Oncology/Hematology, vol. 90, no. 1, pp. 49-57. https://doi.org/10.1016/j.critrevonc.2013.12.003
Ismail, Salima ; Meskawi, Malek ; Hansen, Jens ; Bianchi, Marco ; Tian, Zhe ; Latour, Mathieu ; Graefen, Markus ; Montorsi, Francesco ; Trinh, Quoc Dien ; Perrotte, Paul ; Karakiewicz, Pierre I. ; Sun, Maxine. / A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma. In: Critical Reviews in Oncology/Hematology. 2014 ; Vol. 90, No. 1. pp. 49-57.
@article{34c0c174b82941ffa0fb8424d2f0950a,
title = "A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma",
abstract = "Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies.",
keywords = "Chromophobe, Metastatic, Non-clear cell, Papillary, Renal cell carcinoma, Sorafenib, Sunitinib, Systemic therapy, Targeted therapy, Temsirolimus",
author = "Salima Ismail and Malek Meskawi and Jens Hansen and Marco Bianchi and Zhe Tian and Mathieu Latour and Markus Graefen and Francesco Montorsi and Trinh, {Quoc Dien} and Paul Perrotte and Karakiewicz, {Pierre I.} and Maxine Sun",
year = "2014",
doi = "10.1016/j.critrevonc.2013.12.003",
language = "English",
volume = "90",
pages = "49--57",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma

AU - Ismail, Salima

AU - Meskawi, Malek

AU - Hansen, Jens

AU - Bianchi, Marco

AU - Tian, Zhe

AU - Latour, Mathieu

AU - Graefen, Markus

AU - Montorsi, Francesco

AU - Trinh, Quoc Dien

AU - Perrotte, Paul

AU - Karakiewicz, Pierre I.

AU - Sun, Maxine

PY - 2014

Y1 - 2014

N2 - Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies.

AB - Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies.

KW - Chromophobe

KW - Metastatic

KW - Non-clear cell

KW - Papillary

KW - Renal cell carcinoma

KW - Sorafenib

KW - Sunitinib

KW - Systemic therapy

KW - Targeted therapy

KW - Temsirolimus

UR - http://www.scopus.com/inward/record.url?scp=84895435932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895435932&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2013.12.003

DO - 10.1016/j.critrevonc.2013.12.003

M3 - Article

C2 - 24411587

AN - SCOPUS:84895435932

VL - 90

SP - 49

EP - 57

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -